Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SAT1 | P21673 | 3/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290243 | 0.95 | EPHX1 (0.58) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL6287287 | 0.93 | EPHX1 (0.61) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL12913672 | 0.93 | EPHX1 (0.54) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL12914936 | 0.91 | EPHX1 (0.58) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL13135023 | 0.91 | EPHX1 (0.61) | MEN1KMT2AEPHX1EPHX2 | |
| SCHEMBL12914917 | 0.89 | EPHX1 (0.61) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL6290512 | 0.87 | EPHX1 (0.63) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL14559572 | 0.87 | PAOX (0.59) | CYP2C19MEN1GLAKMT2AEPHX1 | |
| SCHEMBL6287295 | 0.86 | MAPT (0.44) | EPHX1EPHX2TSHRSAT1 | |
| SCHEMBL6289584 | 0.86 | EPHX1 (0.44) | CYP2C19MEN1GLAKMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-6916854-B2 | Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040097642-A1 | Unsaturated compounds containing carbamate terminal groups or urea terminal groups | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | CYP2C19 1012/4885MEN1 4674/4885GLA 4537/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | CYP2C19 2978/4885MEN1 4186/4885GLA 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.